Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Elterman
Dean Sol
DS
Princess Margaret Hospital, Toronto, Ontario, Canada.
Lawrentschuk
Nathan
N
Guns
Emma
E
Hersey
Karen
K
Adomat
Hans
H
Wood
Catherine A
CA
Fleshner
Neil
N
D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000737:chemistry*; D001378:Azasteroids / Q000737:chemistry; D002214:Capsules; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors; D002851:Chromatography, High Pressure Liquid; D017292:Doxazosin / Q000737:chemistry; D004340:Drug Contamination; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000737:chemistry*; D018120:Finasteride / Q000737:chemistry; D006801:Humans; D008297:Male; D008517:Phytotherapy; D011224:Prazosin / Q000031:analogs & derivatives / Q000737:chemistry; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000737:chemistry; D013449:Sulfonamides / Q000737:chemistry; D013607:Tablets; D000077409:Tamsulosin
D000317:Adrenergic alpha-Antagonists; D001378:Azasteroids; D002214:Capsules; D004791:Enzyme Inhibitors; D011799:Quinazolines; D013449:Sulfonamides; D013607:Tablets; D018120:Finasteride; C041226:Terazosin; C047638:alfuzosin; D042944:Cholestenone 5 alpha-Reductase; D000077409:Tamsulosin; D017292:Doxazosin; D000068538:Dutasteride; D011224:Prazosin